<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Tavistock Square, London, WC1H 9JR pmcid: 7200043bmjopen-2020-036936 doi: 10.1136/bmjopen-2020-036936 :" exact="Infectious" post="Diseases: 15061706Protocol Prospective observational study on the pharmacokinetic properties"/>
 <result pre="ribavirin regimen used in routine clinical practice in patients with" exact="Lassa fever" post="in Nigeria EramehCyril12EdeaweOsahogie1AkhidenoPeter12EifediyiGloria1OmansenTill F3WagnerChristine3SarpongFrancisca3KochTill3WichaSebastian4http://orcid.org/0000-0002-3807-473XKurthFlorian35DuraffourSophie6OestereichLisa6PahlmannMeike6OkogbeninSylvanus17Ogbaini-EmovonEphraim1http://orcid.org/0000-0002-6562-0230GüntherStephan6RamharterMichael3GrogerMirjam3[1], Institute of Lassa Fever Research"/>
 <result pre="with Lassa fever in Nigeria EramehCyril12EdeaweOsahogie1AkhidenoPeter12EifediyiGloria1OmansenTill F3WagnerChristine3SarpongFrancisca3KochTill3WichaSebastian4http://orcid.org/0000-0002-3807-473XKurthFlorian35DuraffourSophie6OestereichLisa6PahlmannMeike6OkogbeninSylvanus17Ogbaini-EmovonEphraim1http://orcid.org/0000-0002-6562-0230GüntherStephan6RamharterMichael3GrogerMirjam3[1], Institute of Lassa" exact="Fever" post="Research and ControlIrrua Specialist Teaching HospitalIrruaNigeria[2], Department of MedicineIrrua"/>
 <result pre="Center Hamburg-EppendorfHamburgGermany[4], Department of Clinical PharmacologyUniversity of HamburgHamburgGermany[5], Department of" exact="Infectious" post="Diseases and Pulmonary MedicineCharité Universitätsmedizin BerlinBerlinGermany[6], Department of VirologyBernhard-Nocht-Institut"/>
 <result pre="Hamburg-EppendorfHamburgGermany[4], Department of Clinical PharmacologyUniversity of HamburgHamburgGermany[5], Department of Infectious" exact="Diseases" post="and Pulmonary MedicineCharité Universitätsmedizin BerlinBerlinGermany[6], Department of VirologyBernhard-Nocht-Institut fur"/>
 <result pre="of Clinical PharmacologyUniversity of HamburgHamburgGermany[5], Department of Infectious Diseases and" exact="Pulmonary" post="MedicineCharité Universitätsmedizin BerlinBerlinGermany[6], Department of VirologyBernhard-Nocht-Institut fur TropenmedizinHamburgGermany[7], Department"/>
 <result pre="indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.bmjopen-2020-036936.pdfbmjopen-2020-036936.reviewer_comments.pdfbmjopen-2020-036936.draft_revisions.pdf Abstract Introduction" exact="Lassa fever" post="(LF) is a severe and often fatal systemic disease"/>
 <result pre="Introduction Lassa fever (LF) is a severe and often fatal" exact="systemic" post="disease in humans and affects a large number of"/>
 <result pre="Lassa fever (LF) is a severe and often fatal systemic" exact="disease" post="in humans and affects a large number of countries"/>
 <result pre="large number of countries in West Africa. Treatment options are" exact="limited" post="to supportive care and the broad-spectrum antiviral agent ribavirin."/>
 <result pre="ribavirin regimen different to the WHO recommendation. Apart from a" exact="lower" post="total daily dose the drug is usually administered once"/>
 <result pre="regimen different to the WHO recommendation. Apart from a lower" exact="total" post="daily dose the drug is usually administered once per"/>
 <result pre="in Nigeria. Participants will be adults with PCR-confirmed LF. The" exact="primary" post="objective is to describe classical PK parameters for ribavirin"/>
 <result pre="concentration vs time curve, half-life time T1/2, volume of distribution)." exact="Blood" post="samples will be collected at 0.5, 1, 3, 5,"/>
 <result pre="funders, LF research society and other researchers. Registration details ISRCTN11104750" exact="infectious diseases" post="clinical pharmacology virology Funding German Federal Ministry of Health"/>
 <result pre="intravenous ribavirin treatment, the current standard treatment in patients with" exact="Lassa fever" post="(LF). The results of this study will provide the"/>
 <result pre="not fully representative of unselected patients with LF. Introduction Background" exact="Lassa fever" post="(LF) is an acute febrile illness associated with bleeding,"/>
 <result pre="patients with LF. Introduction Background Lassa fever (LF) is an" exact="acute" post="febrile illness associated with bleeding, organ failure and shock"/>
 <result pre="Background Lassa fever (LF) is an acute febrile illness associated" exact="with bleeding," post="organ failure and shock caused by the Lassa virus"/>
 <result pre="number of low-income and middle-income countries (LMICs) of the West" exact="African" post="region is affected by LF: Ghana, Guinea, Mali, Benin,"/>
 <result pre="zones.4–6 Fatal cases are associated with high viraemia, liver damage," exact="renal failure," post="bleeding, encephalopathy and a shock-like syndrome.4 7–10 Health systems"/>
 <result pre="are associated with high viraemia, liver damage, renal failure, bleeding," exact="encephalopathy" post="and a shock-like syndrome.4 7–10 Health systems in areas"/>
 <result pre="a shock-like syndrome.4 7–10 Health systems in areas where the" exact="disease" post="is endemic and in high-inome countries are overwhelmed due"/>
 <result pre="of LF diagnostics, the risk of nosocomial transmission and the" exact="limited" post="treatment options.11 Following the Ebola virus disease crisis, WHO"/>
 <result pre="transmission and the limited treatment options.11 Following the Ebola virus" exact="disease" post="crisis, WHO has initiated the research and development (R&amp;amp;D)"/>
 <result pre="outbreak of LF ever with hundreds of recorded clinical cases.13" exact="Lassa fever" post="in Irrua The Irrua Specialist Teaching Hospital in Irrua,"/>
 <result pre="monkeys, while initiation of treatment at day 7 conferred only" exact="partial" post="protection. In treated animals, viraemia developed more slowly and"/>
 <result pre="In treated animals, viraemia developed more slowly and peaked at" exact="lower" post="titres than in untreated controls.16 17 The mode of"/>
 <result pre="Similarly, in patients with high viraemia (≥103.6 50% tissue culture" exact="infection" post="dose per millilitre), treatment reduced the case fatality rate"/>
 <result pre="were merged together after the end of the study. Additionally," exact="total" post="participant numbers in treatment and control groups remain unclear."/>
 <result pre="ribavirin are only available for different dosing regimens used for" exact="hepatitis" post="C.25 The multiple dose half-life of ribavirin is estimated"/>
 <result pre="treatment regimen’.27 Apart from a higher loading dose and a" exact="lower" post="total daily dose administered during the course of the"/>
 <result pre="regimen’.27 Apart from a higher loading dose and a lower" exact="total" post="daily dose administered during the course of the Irrua"/>
 <result pre="per day. Rationale for this project LF is a dangerous" exact="infection" post="with a high lethality rate. During the past years,"/>
 <result pre="high lethality rate. During the past years, cases of LASV" exact="infection" post="increased markedly and more evidence on an efficacious therapy"/>
 <result pre="markedly and more evidence on an efficacious therapy of this" exact="disease" post="is direly needed. The standard treatment for patients with"/>
 <result pre="of a treatment standard and evidence-based treatment recommendations for LF." exact="Primary" post="research question What are the PK properties of ribavirin"/>
 <result pre="Irrua ribavirin treatment regimen to patients with LF? Study objectives" exact="General" post="objective The aim of this study is to describe"/>
 <result pre="in comparison and combination with other antiviral agents. Specific objectives" exact="Primary" post="objective Describe the classical PK parameters for ribavirin (maximum"/>
 <result pre="in patients with LF treated with the Irrua ribavirin regimen." exact="Secondary" post="objectives Examine the clinical, haematological, biochemical parameters of the"/>
 <result pre="(RT-PCR) and describe the association of drug exposure with the" exact="viral" post="kinetics. Determine LASV sequences and sequence changes during the"/>
 <result pre="ribavirin regimen on routinely ribavirin-treated patients with LF at the" exact="Lassa fever" post="isolation ward of ISTH that will be included following"/>
 <result pre="that will be included following provision of written informed consent." exact="Primary" post="end point PK parameters of the routine care ribavirin"/>
 <result pre="PK parameters of the routine care ribavirin regimen at ISTH." exact="Secondary" post="end points Viral kinetics in patients routinely treated with"/>
 <result pre="the routine care ribavirin regimen at ISTH. Secondary end points" exact="Viral" post="kinetics in patients routinely treated with the Irrua ribavirin"/>
 <result pre="for diagnosis, research and treatment of LF. The Institute of" exact="Lassa fever" post="Research and Control at ISTH performs molecular LF diagnostics"/>
 <result pre="an assumed PD component (ribavirin stimulating a first-order decay of" exact="viral" post="load). Daily sampling (where coinciding with the safety assessment,"/>
 <result pre="other day as outlined in the study flow chart) of" exact="viral" post="load will allow to detect even weak exposure response"/>
 <result pre="weak exposure response relations. For example, a ribavirin-induced decline in" exact="viral" post="load with a viral elimination half-life of 480 hours compared"/>
 <result pre="For example, a ribavirin-induced decline in viral load with a" exact="viral" post="elimination half-life of 480 hours compared with no effect assuming"/>
 <result pre="patients/cognitively impaired patients). Critical illness (based on investigator’s clinical evaluation)." exact="Severe" post="malnutrition. Haemodialysis. History of haemophilia/bleeding disorder. Haematocrit &amp;lt;30%. History"/>
 <result pre="of haemophilia/bleeding disorder. Haematocrit &amp;lt;30%. History of haemoglobinopathies (ie, sickle-cell" exact="anaemia" post="or thalassaemia major). Known intolerance to ribavirin. Known pregnancy"/>
 <result pre="period of hospitalisation at the Lassa isolation ward but is" exact="limited" post="to 11 days. Further details are outlined in table 1."/>
 <result pre="X X X X Physical examination X Inclusion/Exclusion criteria X" exact="Blood" post="sample for haematology/ biochemistry X X Blood sample for"/>
 <result pre="Inclusion/Exclusion criteria X Blood sample for haematology/ biochemistry X X" exact="Blood" post="sample for PK/PD X X X X X X"/>
 <result pre="X X X X X X X X X X" exact="Blood" post="sample for RT-PCR and virological analyses X X X"/>
 <result pre="X X X X Physical examination   Inclusion/Exclusion criteria  " exact="Blood" post="sample for haematology/biochemistry   X X X Blood sample"/>
 <result pre="criteria   Blood sample for haematology/biochemistry   X X X" exact="Blood" post="sample for PK/PD X X X X X X"/>
 <result pre="X X X X X X X X X X" exact="Blood" post="sample for RT-PCR and virological analyses   X X"/>
 <result pre="at the study site until they are discharged but is" exact="limited" post="to a duration of 11 days. The common duration"/>
 <result pre="LF (such as fatigue, diarrhoea, nausea, vomiting, abdominal pain, bleeding," exact="chest" post="pain, hearing problems and decreased vision) will be assessed"/>
 <result pre="indicated in the study flow) and documented in the eCRF." exact="Blood" post="sampling and analysis Blood will be taken by laboratory"/>
 <result pre="flow) and documented in the eCRF. Blood sampling and analysis" exact="Blood" post="will be taken by laboratory staff of ISTH. Appropriate"/>
 <result pre="personnel involved prior to the commencement of the trial. A" exact="peripheral" post="venous catheter will be inserted on days where more"/>
 <result pre="tablespoons) are additional withdrawals due to the study participation. This" exact="total" post="amount of blood which will be withdrawn does not"/>
 <result pre="which will be withdrawn does not exceed the maximum allowable" exact="total" post="blood draw volumes for clinical research studies.30 Bioanalysis/Ribavirin PK"/>
 <result pre="total blood draw volumes for clinical research studies.30 Bioanalysis/Ribavirin PK" exact="Blood" post="samples will be collected at 0.5, 1, 3, 5,"/>
 <result pre="be collected during screening before the first dose of ribavirin." exact="Blood" post="samples will be centrifuged and the plasma supernatant will"/>
 <result pre="sampling. Plasma samples will be shipped frozen to BNITM for" exact="viral" post="heat inactivation using a validated protocol.31 32 The samples"/>
 <result pre="in the study flow chart until the end of treatment." exact="Blood" post="will be processed directly to analyse viral load by"/>
 <result pre="end of treatment. Blood will be processed directly to analyse" exact="viral" post="load by qRT-PCR. Samples will be aliquoted, frozen and"/>
 <result pre="and to monitor the development of LASV-specific antibodies in blood." exact="Viral" post="growth, isolation of LASV in cell culture, virus sequencing"/>
 <result pre="according to UN2814 regulations.33 Haematological and biochemical safety and tolerability" exact="Blood" post="will be sampled at baseline and then every second"/>
 <result pre="for the participant. The biological risk in this study is" exact="limited" post="to repeated draws of small amounts of venous blood."/>
 <result pre="the blood sampling and bleeding. However, even in haemorrhagic participants" exact="bleeding" post="can be stopped by mechanical compression. Insertion of intravenous"/>
 <result pre="repeat blood draws is associated with risk of local and" exact="systemic" post="infection as in routine procedure. No further biological risks"/>
 <result pre="blood draws is associated with risk of local and systemic" exact="infection" post="as in routine procedure. No further biological risks are"/>
 <result pre="care of patients with LF. Adverse events associated with phlebotomy" exact="General" post="definition of adverse event An adverse event (AE) is"/>
 <result pre="and unintended sign (including an abnormal laboratory finding), symptom or" exact="disease" post="temporally associated with the use of a medicinal (investigational)"/>
 <result pre="awareness of sign or symptom, but easily tolerated. Moderate: enough" exact="discomfort" post="to cause interference with usual activity. Severe: incapacitating with"/>
 <result pre="compliance with GCP which requires reported data to be accurate," exact="complete" post="and verifiable from source documents and that the study"/>
 <result pre="including potential covariates on the impact of drug exposure on" exact="viral" post="kinetics. Description of classical PK parameters A non-compartmental analysis"/>
 <result pre="characterise the typical PK parameters of ribavirin and PK variability." exact="Linear" post="as well as non-linear compartmental PK models will be"/>
 <result pre="the lack of effect) of ribavirin monotherapy on the Lassa" exact="viral" post="kinetics. Semi-mechanistic modelling of the effect time-courses35 will be"/>
 <result pre="the procedures involved, its risks and potential benefits and any" exact="discomfort" post="it may generate.27 This investigator is independent from the"/>
 <result pre="the research project new information become available about the treatment/the" exact="disease" post="that is being studied, the investigator will tell the"/>
 <result pre="References 1FrameJD, BaldwinJM, GockeDJ, et al.Lassa fever, a new virus" exact="disease" post="of man from West Africa. I. Clinical description and"/>
 <result pre="10.1126/science.185.4147.2634833828 3Fisher-HochSP, TomoriO, NasidiA, et al.Review of cases of nosocomial" exact="Lassa fever" post="in Nigeria: the high price of poor medical practice."/>
 <result pre="al.A case-control study of the clinical diagnosis and course of" exact="Lassa fever." post="J Infect Dis1987;155:445–55. 10.1093/infdis/155.3.4453805772 5BauschDG, DembyAH, CoulibalyM, et al.Lassa"/>
 <result pre="CoulibalyM, et al.Lassa fever in guinea: I. epidemiology of human" exact="disease" post="and clinical observations. Vector Borne Zoonotic Dis2001;1:269–81. 10.1089/1530366016002590312653127 6FrameJDClinical"/>
 <result pre="clinical observations. Vector Borne Zoonotic Dis2001;1:269–81. 10.1089/1530366016002590312653127 6FrameJDClinical features of" exact="Lassa fever" post="in Liberia. Rev Infect Dis1989;11 Suppl 4:S783–9. 10.1093/clinids/11.Supplement_4.S7832749109 7McCormickJB,"/>
 <result pre="WalkerDH, KingIJ, et al.Lassa virus hepatitis: a study of fatal" exact="Lassa fever" post="in humans. Am J Trop Med Hyg1986;35:401–7. 10.4269/ajtmh.1986.35.4013953952 8JohnsonKM,"/>
 <result pre="Med Hyg1986;35:401–7. 10.4269/ajtmh.1986.35.4013953952 8JohnsonKM, McCormickJB, WebbPA, et al.Clinical virology of" exact="Lassa fever" post="in hospitalized patients. J Infect Dis1987;155:456–64. 10.1093/infdis/155.3.4563805773 9CumminsD, BennettD,"/>
 <result pre="Trop Med Hyg1992;95:197–201.1597876 10AsogunDA, AdomehDI, EhimuanJ, et al.Molecular diagnostics for" exact="Lassa fever" post="at Irrua specialist teaching Hospital, Nigeria: lessons learnt from"/>
 <result pre="RNA. J Clin Microbiol2010;48:2009–13. 10.1128/JCM.02351-0920351210 16JahrlingPB, HesseRA, EddyGA, et al.Lassa" exact="virus infection" post="of rhesus monkeys: pathogenesis and treatment with ribavirin. J"/>
 <result pre="J Clin Microbiol2010;48:2009–13. 10.1128/JCM.02351-0920351210 16JahrlingPB, HesseRA, EddyGA, et al.Lassa virus" exact="infection" post="of rhesus monkeys: pathogenesis and treatment with ribavirin. J"/>
 <result pre="ribavirin. J Infect Dis1980;141:580–9. 10.1093/infdis/141.5.5806768812 17JahrlingPB, PetersCJ, StephenELEnhanced treatment of" exact="Lassa fever" post="by immune plasma combined with ribavirin in cynomolgus monkeys."/>
 <result pre="ribavirin in cynomolgus monkeys. J Infect Dis1984;149:420–7. 10.1093/infdis/149.3.4206715898 18StephenEL, JahrlingPBExperimental" exact="Lassa fever" post="virus infection successfully treated with ribavirin. Lancet1979;1:268–9. 10.1016/S0140-6736(79)90790-6 19DvoretskaiaVI,"/>
 <result pre="cynomolgus monkeys. J Infect Dis1984;149:420–7. 10.1093/infdis/149.3.4206715898 18StephenEL, JahrlingPBExperimental Lassa fever" exact="virus infection" post="successfully treated with ribavirin. Lancet1979;1:268–9. 10.1016/S0140-6736(79)90790-6 19DvoretskaiaVI, EvseevAA, BogatikovGV,"/>
 <result pre="monkeys. J Infect Dis1984;149:420–7. 10.1093/infdis/149.3.4206715898 18StephenEL, JahrlingPBExperimental Lassa fever virus" exact="infection" post="successfully treated with ribavirin. Lancet1979;1:268–9. 10.1016/S0140-6736(79)90790-6 19DvoretskaiaVI, EvseevAA, BogatikovGV,"/>
 <result pre="of the antiviral efficacy of virazole and ribamidil in experimental" exact="Lassa fever" post="in monkeys]. Vopr Virusol1990;35:151–2.2389569 20CrottyS, CameronCE, AndinoRRna virus error"/>
 <result pre="pharmacology of ribavirin. Semin Liver Dis1999;19:17–24.10349689 27collab: Nigeria Centre for" exact="Disease" post="ControlNational guidelines for Lassa fever cases management2018;13. 28OestereichL, RiegerT,"/>
 <result pre="Liver Dis1999;19:17–24.10349689 27collab: Nigeria Centre for Disease ControlNational guidelines for" exact="Lassa fever" post="cases management2018;13. 28OestereichL, RiegerT, LüdtkeA, et al.Efficacy of Favipiravir"/>
 <result pre="combination with ribavirin in a lethal, immunocompetent mouse model of" exact="Lassa fever." post="J Infect Dis2016;213:934–8. 10.1093/infdis/jiv52226531247 29JinR, FosslerMJ, McHutchisonJG, et al.Population"/>
 <result pre="et al.Population pharmacokinetics and pharmacodynamics of ribavirin in patients with" exact="chronic hepatitis" post="C genotype 1 infection. Aaps J2012;14:571–80. 10.1208/s12248-012-9368-z22639111 30collab: CMRCMaximum"/>
 <result pre="al.Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic" exact="hepatitis" post="C genotype 1 infection. Aaps J2012;14:571–80. 10.1208/s12248-012-9368-z22639111 30collab: CMRCMaximum"/>
 <result pre="C genotype 1 infection. Aaps J2012;14:571–80. 10.1208/s12248-012-9368-z22639111 30collab: CMRCMaximum allowable" exact="total" post="blood draw volumes2006. 31NguyenTHT, GuedjJ, AnglaretX, et al.Favipiravir pharmacokinetics"/>
 <result pre="pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations" exact="lower" post="than targeted. PLoS Negl Trop Dis2017;11:e0005389. 10.1371/journal.pntd.000538928231247 32LoregianA, ScarpaMC,"/>
 <result pre="33collab: World Health OrganizationGuidance on regulations for the transport of" exact="infectious" post="substances 2009-2010, 2008. 34LaouénanC, GuedjJ, PeytavinG, et al.A model-based"/>
 <result pre="exploratory approach to optimize the dosing of Peg-IFN/RBV in cirrhotic" exact="hepatitis" post="C patients treated with triple therapy. CPT Pharmacometrics Syst"/>
</results>
